Quick Search 
Drugs of the Future
Register or sign in

  
 
  
Drugs Fut 2014, 39(9): 627
ISSN 0377-8282
Copyright 2014 Clarivate Analytics
CCC: 0377-8282
DOI: 10.1358/dof.2014.039.09.2207313
 
 
Patritumab: Anti-HER3 monoclonal antibody, oncolytic
Haddley, K.
 
 
Tyrosine kinase receptor family members and their downstream signaling pathways are aberrantly regulated in many cancers. Despite the use of dual therapy targeting two members of the proto-oncogene c-ErbB-1 (EGFR) and c-ErbB-2 (HER2), many patients remain refractory to treatment and resistance occurs rapidly. Upregulation of the HER3 receptor has been implicated as one of the compensatory mechanisms underlying drug resistance. Patritumab is a human monoclonal antibody (MAb) that targets the HER3 receptor, preventing ligand binding-induced activation of downstream signaling. In preclinical studies, patritumab alone inhibited cancer cell and tumor growth. In addition, patritumab synergistically increased the sensitivity of drug-resistant cell lines to anti-EGFR or anti-HER2 agents. Patritumab is currently under development in phase I/III clinical trials in patients with HER3-positive advanced solid tumors, non-small cell lung cancer and metastatic breast cancer. Studies in the U.S., Europe and Japan have shown that the drug is well tolerated.


Full Text: PDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy